High-dose subcutaneous Administration of Biologics: Overcoming barriers through formulation and device innovation
{{output}}
The therapeutic landscape for biologics is rapidly transitioning from intravenous (IV) to subcutaneous (SC) administration, offering significant benefits in cost reduction and patient convenience through enabling treatment in flexible care settings. This shift... ...
